Five hours a day is roughly the difference between a condition that dominates someone’s life and one that sits in the background. New evidence on continuous glucose monitors (CGMs) in type 2 diabetes finds that people using the wearable sensors spend about five more hours daily within their target blood-sugar range compared with traditional fingerstick monitoring, a result that strengthens the push to make the devices standard care beyond type 1 diabetes.
A CGM is a small sensor worn on the arm or abdomen that reads glucose in the fluid under the skin every few minutes and streams it to a phone. The clinical revolution is not the measurement itself but the feedback loop: instead of a handful of snapshots a day, patients see the movie, watching a meal, a walk or a stressful meeting move their glucose in real time and learning, within days, what their own body does.
Time in Range Is the Metric That Matters
Diabetes care has shifted toward ‘time in range’ as a better measure than the quarterly A1C average, because two patients with identical averages can have wildly different daily swings, and the swings drive complications. Five extra hours in range, sustained, is the kind of improvement associated with lower risk to eyes, kidneys and nerves. The National Institute of Diabetes and Digestive and Kidney Diseases describes CGM as a core tool for intensive management, and guidance from the American Diabetes Association has steadily widened its recommendations.
The Access Question
The obstacle is no longer evidence but coverage. Sensors are consumables, replaced every ten to fourteen days, and insurers have historically restricted them to patients on intensive insulin regimens. Studies like this one, showing benefit in broader type 2 populations, are precisely what coverage committees cite when policies loosen. Our technology desk has tracked the parallel consumer story: sensor prices falling, phone integration improving, and wellness users experimenting with the devices for metabolic insight.
What Patients Report Beyond the Numbers
Clinicians say the data understates the effect. Patients describe food choices becoming experiments rather than moral tests, and hypoglycaemia fears, a major source of diabetes distress, easing because alarms replace guesswork. Technology that returns five hours a day of metabolic calm tends also to return something harder to measure: attention, freed for the rest of life.
The Data Changes the Conversation
Perhaps the most underrated effect of continuous monitoring is what it does to the clinical conversation. Traditional diabetes visits revolve around a single number, the A1C, and a certain amount of mutual guesswork about what happened between appointments. CGM replaces that with shared, granular data: patient and clinician looking at the same curves, identifying the same patterns, and agreeing on the same experiments. Endocrinologists describe the shift as moving from interrogation to collaboration, and the dynamic matters because diabetes is a self-managed disease; the person with the condition makes hundreds of micro-decisions daily that no clinician can supervise. Technology that makes those decisions informed rather than guessed at is doing the core work of chronic-disease care. As sensors get smaller, cheaper and more accurate, the remaining question is not whether continuous monitoring becomes standard, but how quickly the payment systems catch up with what patients and doctors already know.
Five hours is also, not coincidentally, about the length of a working afternoon or a full night’s first sleep cycle. Framing the benefit that way explains why patients fight coverage denials so persistently: the device is not returning a laboratory number, it is returning ordinary life, in daily instalments large enough to structure a day around.
